Adapalene/benzoyl peroxide

GALDERMA Showcases Its Continued Commitment to Innovation in Dermatology With New Data to Be Presented at 2022 EADV Congress

Retrieved on: 
Tuesday, September 6, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, PAKT, Research, Professor, Rosacea, KA, Science, Frontiers of Medicine, Congress, AM, Population, IL-31, Thought, Patient, Genetics, RESEARCH, Atopic dermatitis, Sensitive, Woman, Prurigo nodularis, Adapalene, Partnership, Chairperson, Skin, Investment, Acne, Acquisition, Prurigo, Benzoyl peroxide, European Academy of Management, Nervous system, Cetaphil, Onychomycosis, Diagnosis, PM, Perkinsus marinus, Nail, Pharmaceutical industry, Cosmetics, Sculptra, Trifarotene, Methyl aminolevulinate, Ivermectin, Adapalene/benzoyl peroxide, Venereology, Galderma, Dermatology

Galderma has announced it will be showcasing its latest scientific updates at the 31st European Academy of Dermatology and Venereology (EADV) congress in Milan, September 7-10, 2022.

Key Points: 
  • Galderma has announced it will be showcasing its latest scientific updates at the 31st European Academy of Dermatology and Venereology (EADV) congress in Milan, September 7-10, 2022.
  • As the pure-play dermatology leader, Galdermas significant presence at EADV reaffirms its commitment to delivering a truly innovative, science-based portfolio of premium cutting-edge brands and services.
  • Two symposia and eight scientific posters will examine the disease burden, the role of IL-31 in these inflammatory skin conditions and treatments under development.
  • EADV congress to exchange information, share insights and
    GLOBAL HEAD OF RESEARCH & DEVELOPMENT, GALDERMA
    Below is a full list of activities taking place.

Global Acne Market Report 2021 Featuring Major Players - Allergan, Galderma S.A., Valeant Pharmaceutical International, Teva Pharmaceutical Industries. and Johnson & Johnson Services - ResearchAndMarkets.com

Retrieved on: 
Monday, December 13, 2021
General Health, Pharmaceutical, Health, Hospital, Pharmacy, Acne, Salicylic acid, Growth, Dermatology, Retinoid, Central Drugs Standard Control Organisation, Benzoyl peroxide, Atrix, Sale, Income, COVID-19, Clifton Springs Hospital & Clinic, SEC, State and Union Territory Police Forces, Needle, Altrusa International, Inc, Patient, Ayurveda, Infection, Adapalene/benzoyl peroxide, State, Skin, CDSCO, Pharmaceutical industry, Dietary supplement, Health insurance, Isotretinoin

The "Acne Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acne Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the acne drugs market are Allergan, Galderma S.A., Valeant Pharmaceutical International Inc., Teva Pharmaceutical Industries Ltd. and Johnson & Johnson Services, Inc.
  • Acne is a major problem worldwide, close to 90% of people suffer from some sort of acne.
  • The stringent regulations concerning the usage of drugs to treat Acne has an impact on the acne drugs market.

Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States

Retrieved on: 
Monday, June 28, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical trials, Other Health, Anti-acne preparations, Health, Drugs, Clinical medicine, Skin care, Galderma, Health care, L'Oréal, Nestlé, Benzoyl peroxide, Adapalene/benzoyl peroxide

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the worlds largest independent dermatology company, today announced they have signed two exclusive 5-year license agreements for the commercialization of EPSOLAY and TWYNEO in the United States.

Key Points: 
  • Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the worlds largest independent dermatology company, today announced they have signed two exclusive 5-year license agreements for the commercialization of EPSOLAY and TWYNEO in the United States.
  • Innovation is at the heart of our commitment to advancing dermatology, said Baldo Scassellati Sforzolini, Global Head of Research & Development at Galderma.
  • EPSOLAY utilizes a patented technology process to encapsulate benzoyl peroxide within silica-based microcapsules to create a barrier between the medication and the skin.
  • If approved, EPSOLAY has the potential to be the first FDA-approved single-active benzoyl peroxide prescription drug product.

Foamix Announces Enrollment Completion of Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam

Retrieved on: 
Monday, November 18, 2019
Anti-acne preparations, Medicine, Clinical medicine, Organ systems, RTT, Retinoids, Adapalene, Tetracycline antibiotics, Hepatotoxins, Minocycline, Acne, Adapalene/benzoyl peroxide

The trial will evaluate the efficacy and safety of the investigational topical combination foam, which comprises minocycline 3% and adapalene 0.3%.

Key Points: 
  • The trial will evaluate the efficacy and safety of the investigational topical combination foam, which comprises minocycline 3% and adapalene 0.3%.
  • The Phase 2 clinical trial planned to enroll approximately 400 patients, aged 12 years and older, with moderate-to-severe acne vulgaris.
  • Patients are randomized to one of four treatment arms: FCD105 foam, 0.3% adapalene foam, 3% minocycline foam or vehicle foam and will self-apply their assigned treatment once daily for 12 weeks.
  • FCD105 is Foamixs proprietary 3% minocycline, 0.3% adapalene combination foam formulation intended for the treatment of moderate-to-severe acne vulgaris.

Foamix Announces Enrollment of First Patient in Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam

Retrieved on: 
Thursday, September 19, 2019
Anti-acne preparations, Medicine, Clinical medicine, RTT, Organ systems, Adapalene, Minocycline, Acne, Adapalene/benzoyl peroxide, Nadifloxacin

FCD105 combines minocycline and adapalene, which are two leading agents for treating inflammatory and non-inflammatory comedonal acne lesions, respectively, in a convenient, foam-based product.

Key Points: 
  • FCD105 combines minocycline and adapalene, which are two leading agents for treating inflammatory and non-inflammatory comedonal acne lesions, respectively, in a convenient, foam-based product.
  • The Phase 2 clinical trial is expected to enroll approximately 400 patients, aged 12 years and older, with moderate-to-severe acne vulgaris.
  • Patients will be randomized to one of four treatment arms: FCD105 foam, 0.3% adapalene foam, 3% minocycline foam or vehicle foam and will self-apply their assigned treatment once daily for 12 weeks.
  • FCD105 is Foamixs proprietary 3% minocycline, 0.3% adapalene combination foam formulation intended for the treatment of moderate-to-severe acne vulgaris.